Journal article icon

Journal article

Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection

Abstract:

Low-dose human interleukin-2 (hIL-2) treatment is used clinically to treat autoimmune disorders due to the cytokine's preferential expansion of immunosuppressive regulatory T cells (Tregs). However, off-target immune cell activation and short serum half-life limit the clinical potential of IL-2 treatment. Recent work showed that complexes comprising hIL-2 and the anti-hIL-2 antibody F5111 overcome these limitations by preferentially stimulating Tregs over immune effector cells. Although promi...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/j.celrep.2022.111478

Authors


Publisher:
Cell Press
Journal:
Cell Reports More from this journal
Volume:
41
Issue:
3
Article number:
111478
Publication date:
2022-10-18
Acceptance date:
2022-09-20
DOI:
ISSN:
2211-1247
Pmid:
36261022
Language:
English
Keywords:
Pubs id:
1286479
Local pid:
pubs:1286479
Deposit date:
2022-10-30

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP